# 15141 Fixed Dose Correction / naïve and Pre Dialysis (Europe and Asia Pacific)

Study · id `cardio:ct-nct02021370` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02021370](<https://clinicaltrials.gov/study/NCT02021370>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02021370

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.

## Technical summary

Registry record NCT02021370. Randomized; quadruple masking; primary purpose treatment. Start 2014-02-10 (actual); primary completion 2015-09-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 121 participants (enrolled count; ClinicalTrials.gov record NCT02021370, source copy `cardio:ctgov-nct02021370-2019-09-20`, retrieved 2026-10-26)
- Started: 2014-02-10 (actual) (ClinicalTrials.gov record NCT02021370, source copy `cardio:ctgov-nct02021370-2019-09-20`, retrieved 2026-10-26)
- Primary completion: 2015-09-15 (actual) (ClinicalTrials.gov record NCT02021370, source copy `cardio:ctgov-nct02021370-2019-09-20`, retrieved 2026-10-26)
- Completion: 2015-09-23 (actual) (ClinicalTrials.gov record NCT02021370, source copy `cardio:ctgov-nct02021370-2019-09-20`, retrieved 2026-10-26)
- Countries: Australia; Bulgaria; France; Germany; Hungary; Israel; Italy; Japan; Poland; Romania; South Korea; Spain; Türkiye; United Kingdom (ClinicalTrials.gov record NCT02021370, source copy `cardio:ctgov-nct02021370-2019-09-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02021370-2019-09-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: 15141 Fixed Dose Correction / naïve and Pre Dialysis (Europe and Asia Pacific)
- Acronym: DIALOGUE 1
- Condition: Anemia
- Condition: Renal Insufficiency, Chronic
- Intervention (Drug): BAY85-3934
- Intervention (Drug): Placebo
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

## Provenance

Content hash: 71ce0a30521d4de9bf9ade8f5bd2b2065fb6c62fda5316661622c1aad7d93285
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
